Last updated on March 2018

Evaluation of SPN-812 ER High Dose in Adolescents With ADHD

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric)
  • Age: Between 12 - 17 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Healthy male or female subjects, 12-17 years of age, inclusive.
  • Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-V (DSM V), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).
  • Attention Deficit/Hyperactivity Disorder Rating Scale-V, Home Version: Adolescent, Investigator Administered and Scored (ADHD-RS-V) score of at least 28.
  • CGI-S score of at least 4 at screening.
  • Weight of at least 35 kg.
  • Free of medication for the treatment of ADHD for at least one week prior to randomization and agreement to remain so throughout the study.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.